Magenta Therapeutics (Magenta Therapeutics) 6-Month Price Index : N/A (As of May. 05, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-05-05), Magenta Therapeutics's 6-Month Price Index is N/A.

Competitive Comparison of Magenta Therapeutics's 6-Month Price Index

For the Biotechnology subindustry, Magenta Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Magenta Therapeutics (NAS:MGTA) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Magenta Therapeutics (NAS:MGTA) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Magenta Therapeutics 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Magenta Therapeutics (Magenta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139

Website

https://www.magentatx.com

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.

Executives

Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr	officer: CHIEF ACCOUNTING OFFICER	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz	officer: CHIEF FINANCIAL OFFICER	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng	director	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa	officer: Chief Medical Officer	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp	director	2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia	director, officer: CEO and President	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness	officer: See Remarks	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles	director	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140